Organon & Co. OGN
2 targets with a reported result
Releases of the last 3 yearsThe numbers OGN said it expected, in its earnings releases, next to what it then reported for the same period.
Target by target
Each target, with the sentence it came from · release and 10-Q or 10-K
| Target | What the company said | Reported | Result | |
|---|---|---|---|---|
| Revenue Fiscal 2026 |
Given $6.20B release Feb 12, 2026
|
– | Not reported yet | |
The company's wordsFor full year 2026, the company expects to achieve revenue of approximately $6.2 billion and Adjusted EBITDA of approximately $1.9 billion; both measures in-line with 2025 performance. release Feb 12, 2026 | ||||
| Revenue Fiscal 2025 (ended Dec 31, 2025) |
Given $6.12B to $6.33B release Feb 13, 2025
Raised $6.28B to $6.38B release Aug 5, 2025
Lowered $6.20B to $6.25B release Nov 10, 2025
|
$6.22B 10-K filed 2026-02-24 |
Within the range | |
The company's wordsFull year revenue range of $6.125 billion - $6.325 billion, inclusive of · an approximate $200 million year-over-year negative impact from foreign exchange release Feb 13, 2025 Previous Guidance as of Current May 1, 2025 Guidance … Revenue $6.275B - $6.375B release Aug 5, 2025 Previous Guidance as of August 5, 2025 Current Guidance … Revenue $6.200B - $6.250B release Nov 10, 2025 | ||||
| Revenue Fiscal 2024 (ended Dec 31, 2024) |
Given $6.20B to $6.50B release Feb 15, 2024
Narrowed $6.25B to $6.45B release Aug 6, 2024
Raised $6.38B to $6.42B release Oct 31, 2024
|
$6.40B 10-K filed 2025-02-28 |
Within the range | |
The company's wordsFull · year 2024 financial guidance ranges provided; full year revenue range of $6.2 billion to $6.5 billion and Adjusted EBITDA margin in the range of 31.0% to 33.0% release Feb 15, 2024 Guidance range for full year 2024 revenue narrowed to $6.250 billion to $6.450 · billion, mid-point of the range, affirmed; release Aug 6, 2024 Guidance range for full year 2024 revenue narrowed to $6.375 billion to $6.425 billion, mid-point of the range raised by $50 million; · Guidance range for Adjusted EBITDA margin (non-GAAP) revised to 30.0% to 31.0%, inclusive of the $51 million of IPR&D expense incurred in the third quarter release Oct 31, 2024 | ||||
Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (10 releases since 2024-02-15), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.
Sources
The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.
Also
Earnings releases: each release in full.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/OGN/export.csv") into a cell.